Advanced search
1 file | 557.78 KB Add to list

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial

(2019) LANCET. 394(10212). p.1940-1948
Author
Organization
Keywords
Guidelines

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 557.78 KB

Citation

Please use this url to cite or link to this publication:

MLA
Heijerman, Harry GM, et al. “Efficacy and Safety of the Elexacaftor plus Tezacaftor plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation : A Double-Blind, Randomised, Phase 3 Trial.” LANCET, vol. 394, no. 10212, 2019, pp. 1940–48.
APA
Heijerman, H. G., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., … Mccoy, K. S. (2019). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial. LANCET, 394(10212), 1940–1948.
Chicago author-date
Heijerman, Harry GM, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, et al. 2019. “Efficacy and Safety of the Elexacaftor plus Tezacaftor plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation : A Double-Blind, Randomised, Phase 3 Trial.” LANCET 394 (10212): 1940–48.
Chicago author-date (all authors)
Heijerman, Harry GM, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M Mckee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, and Karen S Mccoy. 2019. “Efficacy and Safety of the Elexacaftor plus Tezacaftor plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation : A Double-Blind, Randomised, Phase 3 Trial.” LANCET 394 (10212): 1940–1948.
Vancouver
1.
Heijerman HG, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial. LANCET. 2019;394(10212):1940–8.
IEEE
[1]
H. G. Heijerman et al., “Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial,” LANCET, vol. 394, no. 10212, pp. 1940–1948, 2019.
@article{8646397,
  author       = {Heijerman, Harry GM and McKone, Edward F and Downey, Damian G and Van Braeckel, Eva and Rowe, Steven M and Tullis, Elizabeth and Mall, Marcus A and Welter, John J and Ramsey, Bonnie W and Mckee, Charlotte M and Marigowda, Gautham and Moskowitz, Samuel M and Waltz, David and Sosnay, Patrick R and Simard, Christopher and Ahluwalia, Neil and Xuan, Fengjuan and Zhang, Yaohua and Taylor-Cousar, Jennifer L and Mccoy, Karen S},
  issn         = {0140-6736},
  journal      = {LANCET},
  keywords     = {Guidelines},
  language     = {eng},
  number       = {10212},
  pages        = {1940--1948},
  title        = {Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial},
  url          = {http://dx.doi.org/10.1016/S0140-6736(19)32597-8},
  volume       = {394},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: